"white" test" (= the administration of SMOFlipid retrograde through the cystic duct)
Drug"white" test" (= the administration of SMOFlipid retrograde through the cystic duct)
NCT Number: NCT04523701
Bile leakage (BL) is the most frequent complication after liver resection. This study is to investigate the role of intraoperative administration of SMOFlipid 20% (fat emulsion which allows intraoperative identification of open bile ducts at the liver resection surface when it is administered retrograde through the cystic duct) in terms of prevention of postoperative BL within 30 days after surgery.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Phase 3
Department of Visceral Surgery, Cantonal Hospital of Aarau, Aarau, Switzerland
Bile leakage (BL) is the most frequent complication after liver resection leading to the need of interventional drainage, endoscopic retrograde cholangio pancreatography (ERCP) or even reoperation. Strategies leading to a reduction of the rate of this complication are valuable. SMOFlipid 20% is a fat emulsion which is primary indicated for parenteral nutrition. Because of its fatty content this solution is white. This allows the clear intraoperative identification of open bile ducts at the liver resection surface when it is administered retrograde through the cystic duct. Consequently, open bile ducts can be sutured preventing the postoperative development of BL. If the rate of bile leakages can be reduced, resources for interventions and relaparotomy will be saved. This study is to investigate intraoperative administration of SMOFlipid 20% in terms of prevention of BL within 30 days after surgery.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
"white" test" (= the administration of SMOFlipid retrograde through the cystic duct)
Time frame: within 30 days postoperative
Comparison of the rate of postoperative bile leakage in the control and in the intervention group. This is a binary endpoint defined by the presence or absence of the bile leakage (yes or no). Bile leakage is defined as bilirubin concentration in the drain fluid at least 3 times the serum bilirubin concentration on or after postoperative day 3.
Time frame: within 30 days postoperative
The severity of bile leakage is classified according to its impact on patients´ clinical management. Grade A bile leakage causes no change in patients' clinical management. A Grade B bile leakage requires active therapeutic intervention but is manageable without relaparotomy, whereas in Grade C bile leakage relaparotomy is required.
Time frame: within 30 days postoperative
In-hospital mortality other than related to the bile leakage
Time frame: within 30 days postoperative
In-Hospital morbidity other than related to the bile leakage
Time frame: within 30 days postoperative
Endoscopic retrograde cholangio pancreatography (ERCP) (yes/no)
Time frame: within 30 days postoperative
Percutaneous Transhepatic Cholangio Drainage (PTCD) (yes/no)
Time frame: within 30 days postoperative
Interventional drainage (yes/no)
Time frame: within 30 days postoperative
Re-operation (yes/no)
Time frame: within 30 days postoperative
Intensive care unit (ICU) stay (in days)
Time frame: within 30 days postoperative
Total hospital stay (in days)
Contact information is provided by the study sponsor or research team.
Giulia Manzini
Other
Diagnostic Role of the "White Test" With Lipidic Solution in the Early Intraoperative Identification of Open Bile Ducts for the Prevention of Bile Leakage After Liver Resection- A Randomized Controlled Multicentric Superiority Trial- The BiLe-Trial (Bile Leakage Trial)
Acronym: BiLe
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07511907
Bile Duct Diseases, Bile Duct Disorder
Warsaw, Masovian Voivodeship, Poland
View Trial DetailsNCT01960712
Bile Leakage
Stockholm, Sweden
View Trial Details